Impetigo Market Report 2026

The impetigo market size has grown strongly in recent years. It will grow from $2.4 billion in 2025 to $2.56 billion in 2026 at a compound annual growth rate (CAGR) of 6.6%. The growth in the historic period can be attributed to high prevalence of pediatric skin infections, widespread use of topical antibiotics, poor hygiene and overcrowding conditions, increased awareness of contagious skin diseases, availability of low-cost antibiotic treatments.

The impetigo market size is expected to see strong growth in the next few years. It will grow to $3.27 billion in 2030 at a compound annual growth rate (CAGR) of 6.3%. The growth in the forecast period can be attributed to rising concern over antibiotic resistance, development of novel topical formulations, increasing healthcare access in emerging regions, growing focus on preventive dermatology, improved public health education on skin infections. Major trends in the forecast period include increasing preference for topical antibiotics over systemic therapy, rising focus on early diagnosis and rapid treatment initiation, growing demand for pediatric-specific impetigo treatments, increased emphasis on infection prevention and hygiene awareness, expansion of over-the-counter and outpatient treatment approaches.

The rising prevalence of skin infections is expected to propel the growth of the impetigo market in the coming years. Skin infections occur when harmful microorganisms - such as bacteria, viruses, fungi, or parasites - invade the skin, causing irritation, inflammation, or other symptoms. Factors contributing to the increase in skin infections include high antibiotic resistance, poor hygiene, climate change, weakened immune systems, and increased global travel. Impetigo treatment addresses these infections by targeting bacterial pathogens, typically Streptococcus or Staphylococcus species, through topical or oral antibiotics. These treatments help reduce symptoms like itching and discomfort, prevent the spread of infection, accelerate healing, and minimize the risk of complications or recurrence. For instance, in October 2023, the European Academy of Dermatology and Venereology (EADV), a Switzerland-based nonprofit professional organization, reported that approximately 43% of EU citizens experienced at least one skin disease in the previous 12 months, with fungal skin infections among the most common. Therefore, the rising prevalence of skin infections is driving the impetigo market.

The improvement of healthcare facilities is expected to support the growth of the impetigo market. Healthcare facilities, including hospitals, clinics, and diagnostic centers, provide medical care and services to treat and support patients. Enhancements in healthcare facilities are driven by increased investment in infrastructure, a focus on patient-centered care, population growth, and aging demographics. Improved healthcare facilities facilitate the management and treatment of impetigo by providing better access to specialized dermatological care, expanding the availability of effective treatment options, promoting hygiene practices to prevent infections, and enabling early diagnosis and timely interventions, ultimately improving patient outcomes and reducing the burden of skin infections. For example, in May 2023, the American Health Care Association reported that the United States had 6,129 hospitals, a 0.591% increase from 6,093 hospitals in the previous year.

The rise in healthcare spending is also expected to drive growth in the impetigo market. Healthcare spending encompasses total expenditures on medical care, hospital services, preventive care, medications, research, infrastructure, and administrative costs aimed at maintaining or improving health outcomes. Factors such as an aging population, advancements in medical technology, increasing prevalence of chronic diseases, and rising demand for healthcare services contribute to higher healthcare expenditure. Increased healthcare spending supports the impetigo market by enabling investment in innovative treatments, driving demand for advanced therapeutic solutions, and ensuring broader access to critical care products that enhance patient outcomes. For instance, in May 2024, the UK Office for National Statistics reported that healthcare spending in the UK increased by 5.6% between 2022 and 2023, reaching approximately $317.63 billion (£292 billion).

Major companies operating in the impetigo market are Teva Pharmaceutical Industries Ltd., Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Galderma SA, Dr. Reddy's Laboratories Ltd., Leo Pharma A/S, Torrent Pharmaceuticals Ltd., Almirall S.A, Taro Pharmaceutical Industries Ltd., Cutanea Life Sciences Inc., InfectoPharm Arzneimittel und Consilium GmbH, NovaBay Pharmaceuticals Inc.

North America was the largest region in the impetigo market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the impetigo market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the impetigo market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have moderately impacted the impetigo market by increasing costs for imported antibiotics, active pharmaceutical ingredients, and packaging materials, particularly affecting topical and oral antibiotic segments. Regions reliant on imported generics, such as asia-pacific and parts of africa, face pricing pressures and supply variability. However, tariffs are encouraging domestic manufacturing of dermatological antibiotics, supporting supply chain resilience and long-term market stability.

The impetigo market research report is one of a series of new reports that provides impetigo market statistics, including impetigo industry global market size, regional shares, competitors with a impetigo market share, detailed impetigo market segments, market trends and opportunities, and any further data you may need to thrive in the impetigo industry. This impetigo market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Impetigo is a highly contagious bacterial skin infection, most commonly caused by Streptococcus pyogenes. It usually appears as red sores or blisters that rupture, ooze, and form a yellowish-brown crust. The infection spreads easily through direct skin-to-skin contact or by touching contaminated surfaces.

The main treatment options for impetigo include topical antibiotics, oral antibiotics, and antiseptic soaks. Oral antibiotics are administered as pills or liquid medicines taken by mouth and are typically reserved for cases where the infection is more severe or widespread. The causative pathogens include Staphylococcus aureus, Streptococcus pyogenes, and other bacteria. Impetigo can vary in severity - mild, moderate, or severe - and affects patients across all age groups, including children, adults, and the elderly.

The impetigo treatment market consists of sales of non-bullous impetigo, and bullous impetigo. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.